References
- Ringleb PA, Schellinger PD, Schwark C. Clopidogrel in the management of cerebrovascular events. Int J Clin Pract 2004;4:402–10
- World Health Organization (WHO). Der Europäische Gesundheitsbericht 2002. WHO Regional Office, Copenhagen; 2004. European Series No 97
- Statistisches Bundesamt. Gesundheitberichterstattung des Bundes [Federal Health Report]. www.gbe-bund.de [Nov 22, 2004]
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–39
- Jones L, Griffin S, Palmer S, et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess 2004;8:ii-iv,1–196
- Schellinger PD, Juttler E, Meyding-Lamade UK, Schwark C. The value of platelet inhibitors in secondary prophylaxis of stroke – a review. Fortschr Neurol Psychiatr 2004;5:270–1
- Diener HC, Rupprecht HJ, Willich SN, et al. Cost of atherothrombotic diseases – myocardial infarction (MI), ischaemic stroke (IS) and peripheral arterial occlusive disease (PAD). J Public Health 2005;13:216–24
- Annemans L, Lamotte M, Levy E, Lenne X. Cost-effectiveness of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. JME 2003;6:55–68
- Levy E, Gabriel S, Carita P, Dinet J. An economic evaluation of Clopidogrel in secondary prevention of ischemic events: high risk populations. Value Health 2002;6:477–8
- Rudelli G, Annemans L, Spiesser J, et al. An economic evaluation of clopidogrel vs. Aspirin in secondary prevention of ischemic events in high risk atherothrombotic patients in Italy [poster]. 7th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Hamburg, Germany, Oct 24–26, 2004
- Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003;327:1267–70
- Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health 2004;5:627–35
- Brüggenjürgen B, Rupprecht H-J, Willich SN, et al. Cost of atherothrombotic diseases – myocardial infarction (MI), ischaemic stroke (IS) and peripheral arterial occlusive disease (PAD). J Public Health 2005;13:216–224
- Rote Liste Service GmbH (ed.) Rote Liste Win 2004/I, Version 3.3., ECV Edition Cantor Verlag, 2004
- Delphi-Panel data, costs updated in 2004, data available on request. The whole Delphi process is described in citation 4.
- Hense HW, Schulte H, Löwel H, et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany – results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003;24:937–45
- Schwabe U, Paffrath D (eds.). Arzneiverordnungsreport 2003, Berlin: Springer Verlag, 2004, ISBN 3–540–40188–1
- Hannoveraner Konsensgruppe. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation. Med Klin 2000;95:52–5
- American Heart Association. International Cardiovascular Statistics. 2004. www.americanheart.org
- Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med 2004;12:797–806
- Caro JJ, Migliaccio-Walle K. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. Am J Med 1999;6:568–72
- Probstfield JL. How cost-effective are new preventive strategies for cardiovascular disease? Am J Cardiol 2003;10A:22–7G
- Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002;5:417–30